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Background. Systemic steroids and adjunctive antifungal therapy are the cornerstone in treating allergic bronchopulmonary
aspergillosis (ABPA) in the context of CF. Aim. Evaluate the use of inhaled amphotericin B (iAMB) as antifungal agent in this
context. Methods. Report of 7 CF patients with recurrent or diﬃcult to treat ABPA and failure to taper systemic corticosteroids
treated with AMB deoxycholate (AMB-d) (Fungizone 25mg 3× a week) or AMB lipid complex (ABLC) (Abelcet 50mg twice
weekly). Successful therapy was deﬁned as steroid withdrawal without ABPA relapse within 12 months. Results. Therapy was
successfulin6of7patientstreatedwithiAMB.In5/6,lungfunctionimproved.Thepatientwithtreatmentfailurehasconcomitant
MAC lung infection. Conclusion. Inhaled AMB may be an alternative to commonly used adjunctive antifungal therapy in the
treatment of ABPA. More data are needed on safety and eﬃcacy.
1.Introduction
Allergic bronchopulmonary aspergillosis (ABPA) is a hyper-
sensitivity reaction to Aspergillus species. In children, it is
mostly encountered in the context of cystic ﬁbrosis (CF).
The reported prevalence of ABPA complicating CF lung
disease varies from 6 to 25% depending on the age and
the diagnostic criteria used [1–3]. The clinical diagnosis is
diﬃcult because symptoms are nonspeciﬁc and resemble
bacterial CF airway infection. Diﬀerent diagnostic criteria
have been established based on a combination of clinical and
radiological signs together with the following biochemical
parameters, again none of them being very speciﬁc: elevated
IgE (>500–1000IU/l or a 4-fold rise), eosinophilia, speciﬁc
IgE for A. fumigatus or recombinant antigens (or positive
skin prick test), and precipitins to A. fumigatus.[ 3].
Systemic corticosteroids are still the cornerstone of
therapy starting at a dose of 1-2mg/kg/day for 2-3 weeks
[4], but the pace of tapering is highly variable and
individualized.Adjunctiveantifungalagentslikeitraconazole
(200–400mg/day for several months) may reduce corticos-
teroid need. However, few studies involving only a small
number of CF patients have been published [3, 5].
In our CF center, ABPA is usually treated with a com-
bination of systemic steroids and itraconazole. In patients
with frequent ABPA ﬂares or failure of steroid tapering,
inhaled amphotericin B (iAMB) is considered as alternative
antifungal therapy. Because only scarce data exist [6, 7], we
report our experience with this treatment in 7CF children
with a diﬃcult-to-treat ABPA course.
2. Methods
Inhaled AMB is considered in case of one or more of the
following: (1) insuﬃcient response to initial therapy with
corticosteroids and itraconazole (2) frequent ABPA relapse
during/after steroid withdrawal despite itraconazole treat-
ment (3) failure to taper systemic steroids (4) intolerance
for itraconazole. Data were retrospectively collected on 7CF
patients treated for ABPA with inhaled AMB.
In a ﬁrst step AMB deoxycholate (AMB-d) (Fungizone
Bristol-Meyers Squibb Belgium) was administered as a test
dose (20mg in a concentration of 1mg/ml; nebulization
for 10–15 minutes with a PARI turboboy nebulizer or
Aeroneb Go) [8]. If tolerated, therapy was given 3 times
a week. In case of intolerance for AMB-d (cough, wheeze,2 International Journal of Pediatrics
Table 1
Current
age (years)
Age at Λ
(months)
Age at ﬁrst
ABPA
diagnosis
(years)
Sweat Cl
(meq/l) Genotype
Airway bacterial
pathogens during
ABPA
Indication for
inhaled AMB
Other medica
issues
1( f) 7 11 5.5 106
1717 − 1G >
A/g.3464 3471dup
TCATTGCT and
V1198M
SA, SM, AX,
Chronic PA (age 6) 1I C S
2( f) 11 4 8 85 F508del/F508del SA, AX, 1, 2 ICS, Nissen
3(m) 13 2 8 90 F508del/? B. cepacia (age 8) 2, 3
4( f) 16 7 10 98 F508del/R553X Chronic PA (age 10),
MAC (age 11) 2, 3, 4
MAC,
gastrostomy,
DM
5( f) 19 36 7 120 F508del/F508del SA, HI, SM 2, 3 DM
6( f) 20 1 (NS) 11 ? F508del/F508del Chronic PA (age 16) 2, 3 Nissen
7( f) 20 At birth 9 95 F508del/F508del Chronic PA (age 5) 2, 3 MI, DM
Table 2: Diﬀerent formulation of amphotericin B.
Formul-
ation Carrier Colloidal
type
Size
(µm) Molar ratio
AMB-d Deoxycholate Micelle 0.035
L-AMB PC/DSPG/Chol Liposome 0.08 2:0. 8:1:0. 4
ABLC Phospholipids Lipid ribbon 1.6–11 1:1
ABCD Cholesteryl
sulphate Lipid disk 0.11-
0.12 1:1
PC: phosphatidylcholine; DSPG: distearoylphosphatidylglycerol; Chol:
cholesterol.
and shortness of breath), AMB-lipid complex (ABLC) was
used (Abelcet Wyeth 50mg in a concentration of 5mg/ml,
2 ×/week; nebulization time 10–15 minutes). Duration of
therapy was individualized (see cases and ﬁgures). Choice
of the dosage scheme was mainly based on doses used in
other indications [9] and the reported long half-life of iAMB
in the lung in animal models [10], especially when using a
lipid formulation. Because ABLC has a 1/1molar ratio for
the active product versus the phospholipids (see Table 2), the
weekly dose was about the double compared to AMB-d.
Treatment was considered a success if systemic steroids
could be stopped without ABPA relapse for at least 12
months after steroid withdrawal. Prednisolone was started
at a dose of 1-2mg/kg/day. After 3 weeks, the patient was
seen in clinic, and tapering was started in case of clinical
improvement and fall in IgE. If clinically indicated steroids
were tapered with 5mg every 2 weeks. However, ﬁnal
decision for speed of tapering was made by the treating
CF physician. Improvement of lung function is not used
as an absolute criterion for treatment success in this small
patient series because important comorbidities inﬂuence
lung function evolutions.
Speciﬁc IgE for diﬀerent recombinant Aspergillus anti-
gens were measured (f1, f2, f3, and f4) (ImmunoCAP 1000,
Phadia; cut-oﬀ >0.7Ua/ml).
Patient 1 (WS ◦21-12-2001). This CF girl had a diﬃcult
respiratory course from young age with frequent infec-
tious exacerbations treated with oral and IV antibiotics.
ABPA was ﬁrst diagnosed at age 5based on a respiratory
exacerbation not improving with IV antibiotic treatment
combined with a rise in IgE to 1089kU/l and positive RAST
to the recombinant Aspergillus antigen f6 (4–6.5Ua/ml).
Aspergillus was growing from her sputum. Treatment with
oral steroids and itraconazole (Sporanox Janssen-Cilag 1
× 100mg) was started (Figure 1). Because of persisting
atelectasis of the left upper lobe after 2 weeks of oral steroids
and itraconazole, inhaled AMB-d was added after which the
atelectasiscleared.SputumremainednegativeforAspergillus.
One year after steroid stop and 8 months after inhaled AMB-
d was stopped, ABPA recurred and was successfully treated
with the same combination of prednisolone and antifungal
therapy (itraconazole and AMB-d). She is now 9 month oﬀ
steroids, and inhaled AMB-d was changed to ABLC and will
becontinueduntilatleast1yearfreeofABPA.IgEishowever
rising again, and a new ﬂare is suspected.
Patient 2 (BL ◦13-4-1998). From diagnosis, the respiratory
course of this girl was unstable with frequent infections
and lung inﬁltrates treated with IV antibiotics. Because of
severe gastro-esophageal reﬂux, a Nissen fundoplication was
performed at the age of 5 years. She developed asthmatic
symptoms (in the context of familial atopy and asthma) for
which she has been treated with inhaled steroids.
She was diagnosed with a ﬁrst episode of ABPA based on
arespiratoryexacerbationnotimprovingwithIVantibiotics,
IgE rising from 230kU/l to 500kU/l, eosinophilia (1200/µl),
and a positive RAST for recombinant Aspergillus antigen f4
(between 9 and 43Ua/ml). Aspergillus was cultured from
sputum. She was treated with oral steroids and itraconazole
(Sporanox Janssen-Cilag 1 × 100mg, later 2 × 100mg)
(Figure 2). Two years later there was a relapse of ABPA.
Onlyslowclinicalimprovementwasseenunderoralsteroids,
and itraconazole was replaced by inhaled ABLC. BecauseInternational Journal of Pediatrics 3
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Figure 1
of decreasing lung function and repeated Scedosporium
proliﬁcans in sputum cultures, voriconazole (Vfend Pﬁzer 2
×125mgincreasedto2 ×200mg/dbasedonsubtherapeutic
blood levels) was added. Sputum was initially not clear;
however, she ﬁnally became free of Aspergillus (from march
2009).
Only under combined antifungal therapy, steroids could
be stopped and lung function improved. She is now free of
oral steroids since 1 year.
Patient 3 (BW ◦30-10-1995). This boy developed chronic
lung infection with B. cepacia (multivorans) from the age
of 8. He was diagnosed with ABPA in the same year after
a prolonged respiratory exacerbation being not resolved
despite repeated antibiotic administration. IgE titer was
1635kU/l; speciﬁc IgE for Aspergillus recombinant antigens
were positive only for f3 (1Ua/ml), not for f4 nor f6. He
was treated with oral steroids and itraconazole (Sporanox
Janssen-Cilag 2 × 100mg). One year later, he developed an
ABPA relapse with prolonged course and diﬃcult steroid
tapering (Figure 3). After start of inhaled AMB-d (later
switched to ABCL), steroids could be tapered and ﬁnally
stopped. Inhaled ABCL was stopped after he was free of
steroids and ABPA relapse for 1 year. Sputum cultures
became negative for Aspergillus since start of iAMB.
Despite the resolution of the ABPA, the overall evolution
in this CF patient was unfavorable. He developed a chronic
lung abscess in the right lung for which a right lower lobe
resection was performed at the age of 12. However, chronic
B. cepacia suppurative infection of the remaining right lung
persistedwithdevelopmentofcollapseandafunctionalright
lung. He received a lung transplant at the age of 13.5.
Patient 4 (DK ◦13-1-1993). This girl developed severe
obstructive lung disease and bronchiectasis despite intensive
treatment and frequent courses of IV antibiotics.
T h eﬁ r s te p i s o d eo fA B P Aa tt h ea g eo f1 0( F i g u r e4)
was treated with oral steroids and itraconazole (Sporanox
Janssen-Cilag 2 × 100mg). Several attempts to taper the
steroids failed. From the age of 11 (2004), Mycobacterium
avium-intracellulare(MAC)infectionhasbeendocumented.
Severalcombinationtreatmentshavebeengivenwithlimited
if any success (ethambutol, rifampicin, clarithromycin or
azithromycin, IV amikacin, ciproﬂoxacin or levoﬂoxacin,
interferon gamma 1-b). Lung function continued to decline.
Sputum cultures mainly grew Candida and Aspergillus
species despite longstanding treatment with itraconazole.
Hair loss was reported. Therefore, treatment with voricona-
zole (Vfend Pﬁzer 2 × 120mg) was started. After 1 month of
therapy, slight improvement of lung function and decreased
cough were seen. Voriconazole had to be stopped because
of severe diarrhoea. Posaconazole (Noxaﬁl Schering-Plough
2 × 400mg) was given for a certain period but stopped
because of reimbursement issue (see Figure 3). Inhaled
AMB-d was initiated without clear response and therefore
stopped again. ABLC was only given for short periods of
timebutwasdislikedbythepatient.Sputuminitiallycleared;
however, Aspergillus was isolated again after stop of iAMB.
Voriconazole was successfully reintroduced at a higher dose
(2 × 240mg daily) based on subtherapeutic blood levels,4 International Journal of Pediatrics
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but IgE remains high (Figure 4) and lung function fails to
improve.
Patient 5 (BP ◦25-7-90). ABPAwasdiagnosedbasedonbilat-
eral lung inﬁltrates not improving under adequate antibiotic
therapy combined with raised IgE (3295kU/l) together
with positive RAST and precipitins for A. fumigates.S h e
was treated with oral steroids and itraconazole (Sporanox
Janssen-Cilag 2 × 200mg) but had frequent relapses over the
years (Figure 5).
Only after starting inhaled ABLC, steroids could be
tapered as she has been free of ABPA relapse for almost
2 years although her IgE levels remained high. No more
Aspergillus was cultured from her sputum.
Patient 6 (VM ◦24-7-1989). Childhood years were charac-
terized by rather stable respiratory disease, but since adoles-
cence, respiratory exacerbations became frequent. A Nissen
fundoplication was performed at the age of 13 because
of severe gastro-oesophageal reﬂux. ABPA was diagnosed
at the age of 11 based on a respiratory exacerbation not
improving with IV antibiotics and a high IgE of 3890kU/l.
She was treated successfully with oral steroids and itra-
conazole (Sporanox Janssen-Cilag 2 × 100mg later 2 ×
200mg) (Figure 6). After a relapse 3 years later, tapering of
steroids resulted in frequent ABPA exacerbations. Sputum
cultures were intermittently positive for A. fumigatus, C.
albicans and S. proliﬁcans. After initial start of inhaled ABLC,
compliance was reported as low. Insisting on the importance
of the antifungal therapy ﬁnally resulted in better adherence
resulting not only in successful weaning (more than 2 years
oﬀ steroids) of therapy but also improved lung function. She
remained free of Aspergillus in her sputum under treatment
with iAMB.
Patient 7 (ZB ◦13-10-89). Diagnosis of ABPA was ﬁrst made
at the age of 9 based on a respiratory exacerbation with
a new lung inﬁltrate not clearing with antibiotics. IgE was
881kU/l, with positive speciﬁc RAST for A. fumigatus as well
as positive skin prick test. Aspergillus was never grown from
her sputa. She was ﬁrst treated with oral steroids only. At
the time of the 3rd ABPA episode, itraconazole (Sporanox
Janssen-Cilag 2 × 200mg) was started, but steroid tapering
was diﬃcult.
At the age of 17, inhaled ABLC was started because of
failure to stop the systemic steroids. Steroids were slowly
tapered and successfully stopped after 8 months. She has
b e e nf r e eo fA B P As i n c e2 . 5y e a r sw i t hm o r es t a b l el u n g
function evolution (Figure 7).
3. Discussion
We report the use of inhaled AMB in the treatment
of 7 CF children with diﬃcult-to-treat ABPA. For some
patients AMB was used in combination with itraconazole or
voriconazole. For 5 of the 7 patients treated with inhaled
AMB, treatment was considered a success: patients were
weaned from systemic steroids without ABPA relapse for at
least 12 months. For 2 of these 5 patients, clinical evolution
may well be inﬂuenced by cotreatment with voriconazole6 International Journal of Pediatrics
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although plasma levels were subtherapeutic. The patient that
remained steroid dependent (patient 4) had complex lung
disease with MAC infection. In 4 out of 5 successes, lung
function improved as well. The patient that had progressive
lung function decline, despite successful ABPA treatment,
had B. cepacia lung infection.
A consensus guideline on management of ABPA in CF
has been published [3]. To reduce the burden of A. fumigatus
in the respiratory tract it may be worthwhile to treat with
antifungal medication [4, 11, 12]. Itraconazole is however
lipophilic and may not be well absorbed in CF patients.
Use of proton pump inhibitors may further interfere with
itraconazole absorption. Other possible drug interactions
include CYP3A4 inhibition leading to QT prolongation and
decreased methylprednisolone metabolization. Voricona-
zole, approved for the treatment of invasive aspergillosis, has
a better oral bioavailability. It is however expensive, has a
high potential for drug interactions, and has been associated
with a number of adverse eﬀects [13, 14], and no formal data
exist on its absorption in CF.
In the light of these concerns, use of inhaled medication
like AMB is considered. Data on clinical use mainly concern
prevention and treatment of invasive Aspergillus infections
in neutropenic or lung transplant patients [9]. AMB has
been the treatment of choice for most invasive fungal
infections since its introduction in the 1950s. It has a broad
spectrumofactivityincludingAspergillusfumigatus,Candida
albicans, and Cryptococcus neoformans. Lipid formulations
have been developed to reduce nephrotoxicity after parental
administration while retaining the drug’s activity. Main
diﬀerences between these formulations are listed in Table 2.
Clinically they diﬀer mainly in risk for toxicity, dosing, and
tissue concentration after parental administration [15].
The nebulization of AMB was ﬁrst studied in a rat
model of pulmonary Aspergillus infection. Prophylactic
treatment before fungal inoculation with either formulation
resulted in a signiﬁcantly prolonged survival for all. Mean
concentrations of AMB in the lungs were signiﬁcantly higher
and had a longer half-life with ABLC compared to a similar
dose of AMB-d [16]. The liposomal formulation had the
longest half-life [10].
In lung transplant patients, ABLC and L-AMB are better
tolerated than conventional AMB-d. The deoxycholate salt
used in conventional AMB-d acts as a detergent, impairing
the surfactant function which is a potential toxic eﬀect [17,
18]. In contrast, the liposomal carrier in L-AMB exhibits a
pulmonary surfactant-like function.
The clinical use of inhaled AMB has been recently
reviewed [9]. Several data indicate that nebulizing AMB
is possible and lung deposition can be obtained. Lipid
formulations nebulize better than AMB-d. Few reports are
found on the use of inhaled AMB in the treatment of ABPA.
The use of nebulized AMB-d in the treatment of acute
ABPA in a non-CF boy was reported [19]. A dose of 2.5mg
was given 3 times daily, but duration of therapy was not
mentioned. Data on 5 CF patients treated weekly with L-
AMB was published in abstract form [20]. A dose of 50mg
was given diluted in 8mL aqua. Duration of nebulization
w a sr e p o r t e da s1 5 0m i n u t e so na v e r a g ew h i c hm a k e st h i s
treatment burdensome. Systemic steroids could be stopped8 International Journal of Pediatrics
in4ofthe5patients.Inonepatient,ABPArelapsed7months
after stop of L-AMB. Recently, a short report describes the
successful use of nebulized AMB (5mg two times daily)
in 3 CF children with ABPA in combination with inhaled
budesonide [7].
Based on pharmacokinetic data, we used a 2- or 3-time
per week administration of inhaled AMB. AMB-d was used
when tolerated. Based on possible eﬀects on pulmonary
surfactant, we try however to avoid longstanding use of
AMB-d and switch to ABLC.
With AMB-d, main adverse event was cough and wheeze
induced by the nebulization. These side eﬀects were far less
prominent with ABLC. None of the patients had to stop
the treatment with ABLC because of side eﬀects. Patients
however dislike the treatment because of the bad taste.
We acknowledge that this paper is only a retrospective
case series. Prospective interventional trails will be needed in
order to evaluate the place of inhaled antifungal medication
in the treatment of ABPA.
We are aware that recently several case reports have been
published on the use of omalizumab in ABPA treatment
in CF [21–24]. A prospective randomized trial is currently
conducted in Europe. Even if this therapy proves to be
eﬃcient for this indication, omalizumab will not be suitable
for all CF patients with ABPA, merely because of side eﬀects
but also because of high cost and the necessary 2 weekly in-
hospital administration.
4. Summary
We report on the use of inhaled AMB in the treatment of 7
CFpatientswithdiﬃcult-to-treatABPA.In6ofthe7patients
treated, steroids could be stopped and patients remained free
o fr e l a p s ea f t e rs e v e r a ly e a r so fr e c u r r e n tA B P Ae p i s o d e s .
Based on this limited experience, inhaled AMB may be
considered as antifungal therapy in the context of ABPA
treatment in CF. More data are needed for eﬃcacy and long-
term safety.
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Abbreviations
(i)AMB: (inhaled) Amphotericin B
AMB-d: Amphotericin B deoxycholate
ABLC: Amphotericin B lipid complex
L-AMB: Liposomal amphotericin B
ABCD: Amphotericin B colloidal dispersion
CF: Cystic ﬁbrosis
ABPA: Allergic bronchopulmonary aspergillosis.
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